Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Famous SUVs With Low Energy Utilization In 2024 - 2Geminid meteor shower, one of the year's most reliable, peaks this weekend
- 3Virtual National Science Foundation internships aren’t just a pandemic stopgap – they can open up opportunities for more STEM students
- 4Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
- 5Unraveling the Specialty of Picking Your Ideal Travel Objective
- Strengthening through Wellness: Individual Preparation Achievement
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- Step by step instructions to Open a Lovely Waterway Voyage Insight: Conveniences, Administrations, and Elite Offers
- OECD: Iran war dampening global growth
- Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
- Family Holiday spots
- Hezbollah field commander killed in IDF strikes in Beirut
- Brazil's ex-president Bolsonaro operated on for hernia
- Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
